多西他赛联合氟尿嘧啶、顺铂方案与多西他赛联合氟尿嘧啶、洛铂方案治疗胃癌的疗效比较  

Comparison of efficacy between docetaxel+fluorouracil+cisplatin regimen and docetaxel+fluorouracil+lobaplatin regimen in the treatment of gastric cancer

作　　者：王勇[1] 李国苗[1] 李志斌[1] 钟世寿 Wang Yong;Li Guomiao;Li Zhibin;Zhong Shishou(The Second People's Hospital of Neijiang,Sichuan Neijiang 641000,China)

机构地区：[1]内江市第二人民医院,四川内江641000

出　　处：《现代肿瘤医学》2020年第10期1712-1714,共3页Journal of Modern Oncology

摘　　要：目的:比较多西他赛联合氟尿嘧啶、顺铂方案与多西他赛联合氟尿嘧啶、洛铂方案治疗晚期不可手术胃癌患者的疗效和不良反应。方法:回顾性分析2015年2月至2018年6月126例晚期不可手术的胃癌患者。洛铂组55例:多西他赛+氟尿嘧啶+洛铂,顺铂组71例:多西他赛+氟尿嘧啶+顺铂。洛铂组和顺铂组均21天为一个疗程,连续治疗四个疗程。结果:洛铂组患者客观有效率为50.91%,顺铂组为35.21%,差异无统计学意义(P>0.05)。洛铂组患者疾病控制率达到83.64%,顺铂组为67.61%,差异有统计学意义(P<0.05)。洛铂组患者在恶心、呕吐、白细胞减少和四肢麻木方面发生率明显低于顺铂组,差异有统计学意义(P<0.05)。洛铂组患者血小板减少发生率高于顺铂组,差异有统计学意义(P<0.05)。洛铂组患者严重不良反应的发生率为21.82%,顺铂组为39.44%,差异具有统计学意义(P<0.05)。结论:将多西他赛联合氟尿嘧啶、顺铂方案中的顺铂以洛铂替代,取得了更好的疾病控制率,而患者的不良反应更轻,严重不良反应的发生率也更低,值得临床进一步研究。Objective:To compare the efficacy and side effects of docetaxel+fluorouracil+cisplatin regimen and docetaxel+fluorouracil+lobaplatin regimen in the treatment of advanced non-operative gastric cancer.Methods:From February 2015 to June 2018,126 patients with advanced gastric cancer who were not operable were analyzed retrospectively,including lobaplatin group 55 cases(docetaxel+fluorouracil+lobaplatin)and cisplatin group 71 cases(docetaxel+fluorouracil+cisplatin).The two groups were treated for 21 days for a course of treatment,and continuous treatment for four courses.Results:The objective response rate was 50.91%in lobaplatin group and 35.21%in cisplatin group,with no significant difference(P>0.05).The disease control rate of lobaplatin group was 83.64%,and that of cisplatin group was 67.61%.The difference was statistically significant(P<0.05).The nausea,vomiting,leukopenia and limb numbness in lobaplatin group were significantly less than those in cisplatin group(P<0.05).The incidence of thrombocytopenia in patients with lobaplatin group was higher than that in cisplatin group,and the difference was statistically significant(P<0.05).The incidence of severe adverse reactions was 21.82%in lobaplatin group and 39.44%in cisplatin group(P<0.05).Conclusion:Lobaplatin was used to replace cisplatin in docetaxel+fluorouracil+cisplatin regimen,and the disease control rate was better,and the side effects of patients were lighter,the incidence of serious adverse reactions was lower,which is worthy of further clinical study.

关 键 词：多西他赛 氟尿嘧啶 顺铂 洛铂 胃癌 

分 类 号：R735.2[医药卫生—肿瘤]